Iyer, Gopakumar

Publications

Sort by

Co-Author Network

selected publications

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. The New England journal of medicine. 2024 Academic Article GET IT
Times cited: 8
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. European urology oncology. 2023 Academic Article GET IT
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. European journal of cancer. 2023 Academic Article GET IT
Times cited: 2
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Times cited: 7
Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. The Journal of pathology. 2023 Academic Article GET IT
Times cited: 2
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. The Lancet. Oncology. 2023 Academic Article GET IT
Times cited: 20
Correction: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. 2023 GET IT
KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer. Cancer research. 2023 Academic Article GET IT
Times cited: 13
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1. Urologic oncology. 2023 Review GET IT
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Times cited: 40
Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. 2022 GET IT
Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell reports. 2022 Academic Article GET IT
Times cited: 18
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature communications. 2022 Academic Article GET IT
Times cited: 21
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nature communications. 2022 Academic Article GET IT
Times cited: 18
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO precision oncology. 2022 Academic Article GET IT
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. Clinical genitourinary cancer. 2022 Academic Article GET IT
CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature communications. 2022 Academic Article GET IT
Times cited: 50
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022 Academic Article GET IT
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 4
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. Scientific reports. 2022 Academic Article GET IT
Times cited: 17
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy. JAMA ophthalmology. 2021 Academic Article GET IT
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. Journal of immunotherapy (Hagerstown, Md. : 1997). 2021 Academic Article GET IT
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science translational medicine. 2021 Academic Article GET IT
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature communications. 2021 Academic Article GET IT
Times cited: 91
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. Ophthalmology. Retina. 2021 Academic Article GET IT
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome medicine. 2021 Academic Article GET IT
Times cited: 28
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. BJU international. 2021 Academic Article GET IT
Developing Precision Medicine for Bladder Cancer. Hematology/oncology clinics of North America. 2021 Information Resource GET IT
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 29
OncoTree: A Cancer Classification System for Precision Oncology. JCO clinical cancer informatics. 2021 Academic Article GET IT
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British journal of cancer. 2021 Academic Article GET IT
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. Clinical genitourinary cancer. 2021 Academic Article GET IT
Times cited: 2
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. Cancer medicine. 2020 Academic Article GET IT
Times cited: 15
Systemic therapy in bladder preservation. Urologic oncology. 2020 Information Resource GET IT
Times cited: 1
Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016. European urology. 2020 Article GET IT
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 12
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer. 2020 Academic Article GET IT
Times cited: 23
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European urology. 2020 Academic Article GET IT
Times cited: 29
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 34
Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. Cancer treatment and research communications. 2020 Academic Article GET IT
Times cited: 10
Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 47
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature communications. 2020 Academic Article GET IT
Times cited: 32
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. Clinical genitourinary cancer. 2020 Academic Article GET IT
Times cited: 39
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Scientific reports. 2019 Academic Article GET IT
Times cited: 41
The landscape of immunotherapy in metastatic urothelial carcinoma. Current opinion in urology. 2019 Information Resource GET IT
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies. The American journal of surgical pathology. 2019 Academic Article GET IT
Times cited: 63
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. The Journal of pathology. 2019 Academic Article GET IT
Times cited: 37
Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. Therapeutic advances in urology. 2019 Information Resource GET IT
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. International journal of radiation oncology, biology, physics. 2019 Academic Article GET IT
Times cited: 25
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human pathology. 2019 Academic Article GET IT
Times cited: 31
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 183
Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants. Surgical pathology clinics. 2018 Information Resource GET IT
Times cited: 26
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European urology. 2018 Academic Article GET IT
Times cited: 116
Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions. Current treatment options in oncology. 2018 Information Resource GET IT
Times cited: 10
Genome doubling shapes the evolution and prognosis of advanced cancers. Nature genetics. 2018 Academic Article GET IT
Times cited: 377
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 119
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget. 2018 Academic Article GET IT
Times cited: 26
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 114
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 407
Novel biomarkers in bladder cancer. Urologic oncology. 2018 Information Resource GET IT
Times cited: 5
Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. European urology focus. 2018 Academic Article GET IT
Times cited: 25
HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Academic Article GET IT
Times cited: 600
Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 43
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature communications. 2017 Academic Article GET IT
Times cited: 100
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 90
Granuloma annulare associated with immune checkpoint inhibitors. Journal of the European Academy of Dermatology and Venereology : JEADV. 2017 Article GET IT
Times cited: 21
Activating mutation of PDGFRB gene in a rare cardiac undifferentiated intimal sarcoma of the left atrium: a case report. Oncotarget. 2017 Academic Article GET IT
Times cited: 14
Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. Clinical genitourinary cancer. 2017 Academic Article GET IT
Times cited: 11
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. 2017 GET IT
Times cited: 23
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European urology. 2017 Academic Article GET IT
Times cited: 273
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS medicine. 2017 Academic Article GET IT
Times cited: 250
OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 1720
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature medicine. 2017 Academic Article GET IT
Times cited: 2380
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. Cancer cytopathology. 2017 Academic Article GET IT
Times cited: 27
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 12
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 223
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer research. 2017 Academic Article GET IT
Times cited: 16
Editorial Comment. Urology. 2016 Article GET IT
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer. Cancer investigation. 2016 Academic Article GET IT
Times cited: 12
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 143
Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer. 2016 Academic Article GET IT
Times cited: 55
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European urology. 2016 Academic Article GET IT
Times cited: 69
Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature genetics. 2016 Academic Article GET IT
Times cited: 145
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. The Journal of urology. 2016 Academic Article GET IT
Times cited: 38
Genomic Characterization of Upper Tract Urothelial Carcinoma. European urology. 2015 Academic Article GET IT
Times cited: 210
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 3
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC cancer. 2015 Academic Article GET IT
Times cited: 21
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. The oncologist. 2015 Academic Article GET IT
Times cited: 38
Targeted therapy in advanced bladder cancer: what have we learned?. The Urologic clinics of North America. 2015 Information Resource GET IT
Times cited: 13
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature. 2014 Academic Article GET IT
Times cited: 450
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 513
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. European urology. 2014 Academic Article GET IT
Times cited: 117
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014 Academic Article GET IT
Times cited: 78
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer discovery. 2014 Academic Article GET IT
Times cited: 102
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 71
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 705
Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 9
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 259
Phase II study of everolimus in metastatic urothelial cancer. BJU international. 2013 Academic Article GET IT
Times cited: 154
Specific PPAR gamma agonists may have different effects on cancer incidence. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Article GET IT
Times cited: 4
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer research. 2013 Academic Article GET IT
Times cited: 84
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2012 Academic Article GET IT
Times cited: 171
Genome sequencing identifies a basis for everolimus sensitivity. Science (New York, N.Y.). 2012 Article GET IT
Times cited: 595
Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urologic oncology. 2012 Information Resource GET IT
Times cited: 43
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 31
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. The Journal of pathology. 2011 Academic Article GET IT
Times cited: 77
Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert review of anticancer therapy. 2010 Information Resource GET IT
Times cited: 12

more ...

less ...

Background

education and training

M.D., Vanderbilt University School of Medicine 2003
B.S., Vanderbilt University 1998

Contact

full name

Gopakumar Iyer

VIVO Weill Cornell Medical College

Gopakumar Iyer Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name